Acute Morbidity of Proton Therapy for Prostate Cancer: The Hyogo Ion Beam Medical Center Experience

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2, 2007, Pages 434-443

  Mayahara, Hiroshi ^a   Murakami, Masao ^a   Kagawa, Kazufumi ^a   Kawaguchi, Atsuya ^a   Oda, Yasue ^a   Miyawaki, Daisuke ^a   Sasaki, Ryohei ^b   Sugimura, Kazuro ^b   Hishikawa, Yoshio ^a  

^a HYOGO ION BEAM MEDICAL CENTER   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute morbidity; Androgen suppression therapy; Prostate cancer; Proton therapy; Radiotherapy

Indexed keywords

MEDICAL PROBLEMS; PHOTONS; RADIOTHERAPY;

ACUTE MORBIDITY; ANDROGEN SUPPRESSION THERAPY; PROSTATE CANCER; PROTON THERAPY;

ONCOLOGY;

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; PROSTATE SPECIFIC ANTIGEN; TAMSULOSIN;

ADULT; AGED; ARTICLE; CANCER STAGING; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSIMETRY; GASTROINTESTINAL DISEASE; GLEASON SCORE; HUMAN; INCIDENCE; ION THERAPY; IRRADIATION; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROTON THERAPY; RADIATION DOSE; TOXICITY; UROGENITAL TRACT DISEASE;

AGED; ANALYSIS OF VARIANCE; GASTROINTESTINAL TRACT; HEMATURIA; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTONS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TUMOR BURDEN; URINATION DISORDERS; UROGENITAL SYSTEM;

EID: 34548475583     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.03.009     Document Type: Article

References (48)

1. Archambeau J.O., Bennett G.W., Levine G.S., et al. Proton radiation therapy. Radiology 110 (1974) 445-457
2. Suit H. The Gray Lecture 2001: Coming technical advances in radiation oncology. Int J Radiat Oncol Biol Phys 53 (2002) 798-809
3. Raju M.R. Proton radiobiology, radiosurgery and radiotherapy. Int J Radiat Biol 67 (1995) 237-259
4. Yonemoto L.T., Slater J.D., Rossi C.J., et al. Combined proton and photon conformal radiation therapy for locally advanced carcinoma of the prostate: Preliminary results of a phase I/II study. Int J Radiat Oncol Biol Phys 37 (1997) 21-29
5. Slater J.M., Archambeau J.O., Miller D.W., et al. The proton treatment center at Loma Linda University Medical Center: Rationale for and description of its development. Int J Radiat Oncol Biol Phys 22 (1992) 383-389
6. Slater J.D., Yonemoto L.T., Rossi C.J., et al. Conformal proton therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 42 (1998) 299-304
7. Slater J.D., Rossi C.J., Yonemoto L.T., et al. Proton therapy for prostate cancer: The initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 59 (2004) 348-352
8. Kagawa K., Murakami M., Hishikawa Y., et al. Preclinical biological assessment of proton and carbon ion beams at Hyogo Ion Beam Medical Center. Int J Radiat Oncol Biol Phys 54 (2002) 928-938
9. Hishikawa Y., Kagawa K., Murakami M., et al. The cancer treatment system at Hyogo Ion Beam Medical Center (HIBMC). J Jpn Soc Ther Radiol Oncol 14 (2002) 73-77
10. Hishikawa Y., Kagawa K., Murakami M., et al. Usefulness of positron-emission tomographic images after proton therapy. Int J Radiat Oncol Biol Phys 53 (2002) 1388-1391
11. Hishikawa Y., Oda Y., Mayahara H., et al. Status of the clinical work at Hyogo. Radiother Oncol 73 Suppl. 2 (2004) 38-40
12. Hara I., Murakami M., Kagawa K., et al. Experience with conformal proton therapy for early prostate cancer. Am J Clin Oncol 27 (2004) 323-327
13. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41 (1998) 491-500
14. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th ed. In: Sobin L.H., and Wittekind C. (Eds) (1997), John Wiley, New York
15. National Cancer Institute (NCI). Common toxicity criteria, version 2.0 (1999), National Cancer Institute, Bethesda
16. Cox J.D., Stetz B.S., and Pajak T.F. Toxicity criteria of Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
17. Pollack A., Zagers G.K., Starkschall G., et al. Conventional vs. conformal radiotherapy for prostate cancer: Preliminary results of dosimetry and acute toxicity. Int J Radiat Oncol Biol Phys 34 (1996) 555-564
18. Leibel S.A., Heimann R., Kutcher G.J., et al. Three-dimensional conformal radiation therapy in locally advanced carcinoma of the prostate: Preliminary results of a phase I dose-escalation study. Int J Radiat Oncol Biol Phys 28 (1994) 55-65
19. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17 (1999) 517-522
20. Nuyttens J.J., Milito S., Rust P.F., et al. Dose-volume relationship for acute side effects during high dose conformal radiotherapy for prostate cancer. Radiother Oncol 64 (2002) 209-214
21. Teh B.S., Mai W., Uhl B.M., et al. Intensity modulated radiation therapy (IMRT) for prostate cancer with the use of a rectal balloon for prostate immobilization: Acute toxicity and dose-volume analysis. Int J Radiat Oncol Biol Phys 49 (2001) 705-712
22. Zelefsky M.J., Fuks Z., Hunt B.A., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
23. Meerleer G.D., Vakaet L., Meersschout S., et al. Intensity-modulated radiotherapy as primary treatment for prostate cancer: Acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60 (2004) 777-787
24. Zelefsky M.J., Ginor R.X., Fuks Z., et al. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 45 (1999) 567-570
25. Gelblum D.Y., Potters L., Ashley R., et al. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys 45 (1999) 59-67
26. 125I prostate implantation. Int J Radiat Oncol Biol Phys 47 (2000) 353-360
27. Hanks G.E., Schultheiss T.E., Hunt M.A., et al. Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys 31 (1995) 25-29
28. Karlsdottir A., Johannessen D.C., Muren L.P., et al. Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer. Radiother Oncol 71 (2004) 43-53
29. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453-460
30. Zelefsky M.J., Leibel S.A., Burman C.M., et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29 (1994) 755-761
31. Valicenti R.K., Winter K., Cox J.D., et al. RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?. Int J Radiat Oncol Biol Phys 57 (2003) 614-620
32. Guinan P., Didomenico D., Brown J., et al. The effect of androgen deprivation on malignant and benign prostate tissue. Med Oncol 14 (1997) 145-152
33. Reuter V.E. Pathological changes in benign and malignant prostatic tissues following androgen deprivation therapy. Urology 49 3A Suppl. (1997) 16-22
34. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
35. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
36. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 292 (2004) 821-827
37. Tinger A., Michalski J.M., Cheng A., et al. A Critical evaluation of the planning target volume for 3-D conformal radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 213-221
38. Zelefsky M.J., Crean D., Mageras G.S., et al. Quantification and predictors of prostate position variability in 50 patients evaluated with multiple CT scans during conformal radiotherapy. Radiother Oncol 50 (1999) 225-234
39. Alasti H., Petric M.P., Catton C.N., et al. Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 869-884
40. Hanks G.E., Hanlon A.L., Schultheiss T.E., et al. Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41 (1998) 501-510
41. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Future evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 35 (1996) 251-257
42. Chism D.B., Horwitz E.M., Hanlon A.L., et al. Late morbidity profiles in prostate cancer patients treated to 79-84 Gy by a simple four-field coplanar beam arrangement. Int J Radiat Oncol Biol Phys 55 (2003) 71-77
43. Zelefsky M.J., Leibel S.A., Kutcher G.J., et al. Three-dimensional conformal radiotherapy and dose escalation: Where do we stand?. Semin Radiat Oncol 8 (1998) 107-114
44. Pickett B., Roach III M., Verhey L., et al. The value of nonuniform margins for six-field conformal irradiation of localized prostate cancer. Int J Radiat Oncol Biol Phys 32 (1995) 211-218
45. Hanks G.E., Hanlon A.L., Pinover W.H., et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys 46 (2000) 823-832
46. Mock U., Bogner J., Georg D., et al. Comparative treatment planning on localized prostate carcinoma. Strahlenther Onkol 181 (2005) 448-455
47. Fiorino C., Cozzarini, Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: Analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
48. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Later rectal bleeding after conformal radiotherapy of prostate cancer (II): Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 (2001) 685-698